EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort

Jasmohan S Bajaj, Patrick S Kamath, Florence Wong, Qing Xie, Ramazan Idilman, Mark Topazian, Wai-Kay Seto, Aldo Torre, Peter Hayes, Peter George, Mario Alvares-da-Silva, Brian J Bush und 3 weitere

Clinical and Molecular Hepatology · 01.07.2026 · 32 (3) · 1321-1332

DOI: 10.3350/cmh.2026.0228 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2026. Verfasst von Jasmohan S Bajaj und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, USA. jasmohan.bajaj@vcuhealth.org. Hauptthemen laut MEDLINE: Rifaximin, Liver Cirrhosis, Anti-Bacterial Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: VA Merit Review, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Infections with drug-resistant organisms (DROs) are associated with poor outcomes in cirrhosis. Rifaximin, widely used for hepatic encephalopathy (HE), could promote cross-resistance, but data regarding clinical impact are conflicting.

Aim

Determine predictors of DROs in a global cirrhosis inpatient cohort focusing on preadmission rifaximin use.

Methods

From the global CLEARED consortium, we focused on cirrhosis inpatients with infections on/during admission. Clinical/demographic/medication, especially rifaximin details were recorded. The primary outcome was DRO development. Multivariable regression for DRO including clinical, medications, and country income was performed.

Results

2,949 infected inpatients (55.3 years, 62.9% male) were included. 12.2% of all and 24.4% of culture-positive infections developed DROs; these patients had higher HE (39 vs. 31%, P=0.003), hepatorenal syndrome (25 vs. 19%, P=0.006), lactulose (55 vs. 47%, P=0.008) and rifaximin use (34 vs. 27%, P=0.006) on crude comparisons but country-income distributions were similar. 29.7% were on pre-admission rifaximin, mostly HE-related; they had more advanced cirrhosis and from low/low-middle-income countries. Daptomycin was used in 1.5%, linked with DROs (5.0 vs. 1.0%, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifaximinLiver CirrhosisAnti-Bacterial AgentsHumansMaleFemaleMiddle AgedHepatic EncephalopathyRifamycinsAgedHepatorenal SyndromeCohort StudiesLactuloseInpatientsDrug Resistance, Bacterial

Stichwörter der Autor:innen

Antibiotic overuseCLEARED consortiumDaptomycinDisparitiesInfections

Substanzen

RifaximinRifamycinsAnti-Bacterial AgentsLactulose

Autor:innen und Institutionen

  • Department of Medicine, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, USA. jasmohan.bajaj@vcuhealth.org.
  • Department of Medicine, Mayo Clinic School of Medicine, Rochesterc.
  • Department of Medicine, University of Toronto, Toronto, Canada.
  • Department of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Medicine, Ankara University, Ankara, Türkiye.
  • Department of Medicine, St Paul Millenium Hospital, Addis Ababa, Ethiopia.

Förderung

  • VA Merit Review
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Bajaj, J. S., Kamath, P. S., Wong, F., Xie, Q., Idilman, R., Topazian, M., Seto, W. K., Torre, A., Hayes, P., George, P., Alvares-da-Silva, M., Bush, B. J., Silvey, S., Choudhury, A., & CLEARED Investigators (2026). Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort. Clinical and Molecular Hepatology, 32(3), 1321-1332. https://doi.org/10.3350/cmh.2026.0228

Vancouver

Bajaj JS, Kamath PS, Wong F, Xie Q, Idilman R, Topazian M, et al. Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort. Clinical and Molecular Hepatology. 2026;32(3):1321-1332. doi:10.3350/cmh.2026.0228

BibTeX
@article{Bajaj2026,
  author = {Bajaj, Jasmohan S and Kamath, Patrick S and Wong, Florence and Xie, Qing and Idilman, Ramazan and Topazian, Mark and Seto, Wai-Kay and Torre, Aldo and Hayes, Peter and George, Peter and Alvares-da-Silva, Mario and Bush, Brian J and Silvey, Scott and Choudhury, Ashok and CLEARED Investigators, CLEARED Investigators},
  title = {Lack of association between rifaximin and drug-resistant infections: a global multicenter inpatient cirrhosis cohort},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {3},
  pages = {1321--1332},
  doi = {10.3350/cmh.2026.0228}
}
Kostenlos starten →